Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
From July to September 2020, in a first uncontrolled cohort study, 478 patients who were hospitalized at Bicêtre hospital for COVID-19 and who survived were evaluated at 4 months (publication accepted at JAMA). The current project aims to bring together the means to continue this work during the 2nd epidemic wave.
From 15th July to 18th September, 2020, in a first uncontrolled cohort study (Multi-Expertise Consultation of Bicêtre After Covid-19, COMEBAC), we evaluated at four months the surviving patients who were hospitalized at the Bicêtre hospital for COVID-19 during the 1st wave of the epidemic in France and having survived this hospitalization. This cohort included 478 patients. The article resulting from the analysis of the data collected is accepted for publication in JAMA.
This evaluation, the aim of which was both clinical and scientific, was carried out largely thanks to human and material resources then demobilized because of the epidemic and thanks to the investment of doctors and psychologists who carried out the work in addition to their usual work.
The response to the current call for projects aims to bring together the means to continue this monitoring work during the 2nd epidemic wave, while the means and staff are this time completely mobilized by the care of patients with COVID-19 and other. It also aims to raise funds that will allow an in-depth analysis of the residual symptoms presented by the patients.
The current project aims to continue the work started with the COMEBAC "1st wave" cohort with:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients from the 1st epidemic wave | One year after their discharge from the initial hospitalization, patients who presented symptoms during the evaluation in COMEBAC "1st wave" in summer 2020 will benefit from a telephone assessment on the same schedule as that detailed above. If symptoms persist, they will be called to the day hospital for an assessment similar to the one detailed above. |
| |
| Patients from the 2nd epidemic wave | As during the evaluation carried out during the 1st wave, the detection of persistent symptoms will be done in two stages:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Teleconsultation | Other | Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms:
Edition 2021 ◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of respiratory, cognitive and psychological symptoms presented at 6 months of hospitalization for COVID-19. | nature and prevalence of symptoms persisting at 6 months of an episode of COVID-19 requiring hospitalization | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Difference between the prevalence of residual symptoms between patients hospitalized during the 1st wave of the epidemic in France (from the COMEBAC "1st wave" study) and those of the current study | risk factors for the various sequelae of COVID-19 | 6 months |
| Association between patient characteristics and the prevalence of residual symptoms. |
Not provided
For the 6-month evaluation of patients from the 2nd epidemic wave
Inclusion criteria
Exclusion criteria
For the 12-month evaluation of patients from the 1st epidemic wave
Inclusion criteria
◌ Presence of general, cognitive, psychological and respiratory symptoms during the assessment made at 4 months in COMEBAC "1st wave"
Exclusion criteria
Not provided
Not provided
Not provided
Patients from the 1st epidemic wave Patients from the 2nd epidemic wave
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tai PHAM | Contact | +33145217245 | tai.pham@aphp.fr |
| Name | Affiliation | Role |
|---|---|---|
| Tai PHAM | Bicêtre Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bicetre hospital | Recruiting | Le Kremlin-Bicêtre | 94270 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005355 | Fibrosis |
| D013313 | Stress Disorders, Post-Traumatic |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D040921 | Stress Disorders, Traumatic |
| D000068099 | Trauma and Stressor Related Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D019114 | Remote Consultation |
| D000554 | Ambulatory Care Facilities |
| ID | Term |
|---|---|
| D012017 | Referral and Consultation |
| D011364 | Professional Practice |
| D009934 | Organization and Administration |
| D006298 | Health Services Administration |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Outpatient clinic | Other | During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment.
|
|
effect of the therapeutic changes that occurred between the 1st and 2nd wave of COVID-19 on these persistent symptoms. |
| 6 months |
| Association between residual symptoms and the type of SARS-CoV-2 variant | residual symptoms of COVID-19 according to the SARS-CoV-2 variants responsible | 6 months |
| Prevalence of respiratory, neurological, cognitive and psychological symptoms presented at 6 months of hospitalization for COVID-19 which occurred during the 1st epidemic wave. | residual symptoms of COVID-19 one year after COVID-19 that occurred during the 1st epidemic wave | 6 months |
| D001523 | Mental Disorders |
| D017216 | Telemedicine |
| D003695 | Delivery of Health Care |
| D010346 | Patient Care Management |
| D006268 | Health Facilities |
| D005159 | Health Care Facilities Workforce and Services |